|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Systemic Lupus Erythematosus - Market Set to Enter Era of Biologic Therapies
Datamonitor, March 2008, Pages: 108
SLE is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. Therapy is largely off-label and a huge demand exists for new SLE therapies because of the potential for serious side effects from drugs currently used in the management of the disease.
Scope
- Assessment of patient size across the seven major and additional emerging markets, including split by sex and race where available.
- Commercial and clinical assessment of the therapies in the developmental pipeline.
- Opinion of the market potential from a range of physicians involved in SLE treatment and research.
- An update of the challenges facing the design of clinical trials
Highlights of this title
The SLE market will enter an era of targeted therapies thanks to greater understanding of disease mechanisms. Rituxan/MabThera (rituximab) is the most advanced pipeline candidate and will be the first product approved in the last 40 years. It is already used off-label in severe, refractory patients, with maximum estimated sales $650m.
Caution must be maintained as products for SLE have been prone to failure, as evidenced by La Jollas Riquent, Genelabss Prestara and Aprevas CellCept. Companies must learn from past mistakes by improving SLE clinical trial design and communicating fully with regulatory agencies.
The SLE patient population in the seven major markets is estimated to be 430,000 in 2008. However, the combined SLE patient population in Mexico, China and India could be a minimum of 0.9 billion in 2008, suggesting pharmaceutical companies should seek product approval in emerging markets.
Key reasons to purchase this title
- Understand the key opportunities and threats in the SLE market
- Assess the commercial potential of the products in the late-stage pipeline
- Gain insight into opinion leaders thoughts on the challenges facing the SLE market
Customers who bought this item also bought
Competitor Analysis: Systemic Lupus Erythematosus (SLE)
Stakeholder Opinions: Systemic Lupus Erythematosus - On the Verge of a Breakthough
Systemic Lupus Erythematosus Imprecise Segmentation Complicates Treatment Algorithms
Systemic Lupus Erythematosus: The Wait For Lupus-Specific Treatments
Emerging Therapies to Treat Lupus Erythematosus
Systemic Lupus Erythematosus: A Route to Other Autoimmune Disease
Disease and Therapy Review: Systemic Lupus Erythematosus
Could a Validated Biomarker Transform the Lupus Market?
Autoimmune And Inflammation Lupus
Autoimmune and Inflammation - Lupus Drug Pipeline Report
Commercial and Pipeline Insight: Systemic Antifungals
Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
|
|
|
